Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer

Cancer Treat Rep. 1981 May-Jun;65(5-6):517-9.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Alopecia / chemically induced
  • Carcinoma, Squamous Cell / drug therapy*
  • Cisplatin / administration & dosage*
  • Cisplatin / adverse effects
  • Dianhydrogalactitol / administration & dosage*
  • Dianhydrogalactitol / adverse effects
  • Doxorubicin / administration & dosage*
  • Doxorubicin / adverse effects
  • Drug Evaluation
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Lung Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Prognosis
  • Sugar Alcohols / administration & dosage*
  • Thrombocytopenia / chemically induced

Substances

  • Sugar Alcohols
  • Dianhydrogalactitol
  • Doxorubicin
  • Cisplatin